Clinical Information for Respi GX and Infectious Disease Testing
Innovative Genomics offers a comprehensive menu of tests for a wide range of PGx, infectious disease (including COVID-19), and the list is constantly expanding as we proceed through additional research and approvals.
Respi GxTM utilizes quantitative Real-Time Polymerase
Chain Reaction (qPCR) to rapidly analyze your
patient’s sample in 24 hours. RT-PCR technology
precisely detects the correct pathogens(s) and
identifies antibiotic drug resistance. This allows
providers the ability to prescribe timely and effective
treatment.
Rapid and accurate solution eliminates guesswork in diagnosing and treating upper respiratory infections
Acute respiratory infection is a significant cause of morbidity and mortality in young, geriatric and immunocompromised patients. Co-infection is also high within these populations and access to advanced technology is essential to detect multiple pathogens at once. False negative test results can lead to a delayed diagnosis and poor clinical outcomes.
Respi GxTM quickly identifies pathogens and detects potential antibiotic resistance, so effective treatment can begin sooner.
- PCR, a molecular technique, can be used to precisely analyze the genetic material of pathogens
- Provides a more definitive diagnosis than POC antigen assays
- 24-hour turnaround from specimen receipt.
- More accurate than conventional culture
- CAP and CLIA accredited
- CAP and CLIA accredited
Helps improve clinical confidence and decrease patient risks
- Detects polymicrobial infections
- Unaffected by concurrent antibiotic use
- Identifies potential antibiotic resistance
- Aids in quick clinical decision-making
- Reduces false negative results
- Aids in antibiotic stewardship
- Reduces potential unnecessary drug exposure and adverse events
- Respi GxTM Panel Menu
- Acinetobacter baumanii
- Adenovirus Respiratory (HAdV-B)
- Aspergillus fumigatus
- Aspergillus niger
- Bordetella pertussis
- Bordetella parapertusis
- Bordetella bronchiseptica
- Chlamydia trachomatis
- Chalamydophila pneumoniae
- Citrobacter freundii
- Coccidioides immitis
- Coccidioides posadasii
- Coronavirus (229E, NL63, OC43, HKU1)
- Cytomegalovirus (CMV, Human herpesvirus-5)
- Escherichia coli
- Enterovirus (A,B,C,D)
- Haemophilus influenzae
- Herpes simplex virus (HSV-1, HSV-2)
- Human Herpes Virus 3 (Varicella zoster virus)
- Human metapneumovirus
- Influenza virus (A,B)
- Klebsiella pneumoniae
- Legionella pneumophila
- Moraxella catarrhalis
- Mycobacterium tuberculosis
- Mycobacterium avium
- Mycobacterium intracellulare
- Mycobacterium kansasii
- Mycoplasma pneumoniae
- Parainfluenza virus (Types 1,2,3,4)
- Proteus mirabilis
- Pseudomonas aeruginosa
- Respiratory syncytial virus
- Rhinovirus (A, B, C)
- Serratia marcescens
- Staphylococcus aureus
- Streptococcus agalactiae (GBS)
- Streptococcus pneumoniae
- Streptococcus pyogenes
- Antibiotic Resistance Panel Menu
- VanA, VanB (Vancomycin resistance genes)
- MecA(Methicillin resistance gene)
- ErmB, C; MefA (Macrolide lincosamide streptogramin resistance)
- QnrA2(Fluoroquinolone resistance genes)
- Tet M (Tetracycline resistance genes)
- SHV, KPC Groups(Class A beta lactamase)
- CTX-M1 (15), M2 (2), M9 (9), M8/25 Groups (Class A beta lactamase)
- IMP, NDM, VIM Groups(Class B metallo beta lactamase)
- ACT, MIR, FOX, ACC Groups(AmpC beta lactamase)
- OXA-48, -51(Class D oxacillinase)
- PER-1/VEB-1/GES-1Groups (Minor extended spectrum beta lactamases)
- Dfr (A1, A5), Sul (1,2) Probes(Trimethoprim / sulfamethoxazole resistance)
How We Bill For Testing
